Dysfunction of microglia is known to play an important role in Alzheimer’s disease (AD). Here, we investigated the role of RIPK1 in microglia mediating the pathogenesis of AD. RIPK1 is highly ...

Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with amyotrophic lateral sclerosis (ALS) Denali to receive a milestone payment of $40 million from ...

In a recent study published in the journal Nature Cell Biology, researchers investigated how N-acetyltransferase (NAT)-mediated post-translational modification, acetylhypusination, regulates insulin ...

The IKK complex protects cells from death by inactivating RIPK1, thereby revealing an unexpected NF-kB-independent new role of the IKK complex, investigators have revealed. The team of Prof. Bertrand ...

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license ...

Scientists at St. Jude Children's Research Hospital have discovered a new way that the molecule RIPK1 leads to cell death in infected, damaged or unwanted cells showing that more than one mechanism ...

In a study published in the Proceedings of the National Academy of Sciences, researchers have revealed that amyloid fibrils formed by necroptosis mediators, RIPK1 and RIPK3, don't just form within ...

Eli Lilly will partner with Rigel Pharmaceuticals to co-develop and commercialize Rigel’s Phase II-bound R552 for all indications—which they emphasized would include autoimmune and inflammatory ...

Just two weeks after Sanofi laid out $125 million to take a stake in two RIPK1 inhibitors being developed by Denali, the two companies are advancing one of those drugs into clinical trials in three of ...

Receptor-interacting protein kinase 1 (RIPK1) regulates cell cycle and counteracts necroptosis, and is hence considered a target to watch in necroptosis-related conditions such as cancer or ...